A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Upon determination of eligibility, all patients will be receive:
Tarceva + Avastin
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy of the combination of Tarceva and Avastin
18 months
No
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI GU 17
NCT00193154
February 2003
October 2013
Name | Location |
---|---|
Medical Oncology LLC | Baton Rouge, Louisiana 70809 |
Grand Rapids Oncology Program | Grand Rapids, Michigan 49503 |